https://mindmedicinelaw.com/briefing/dea-seeks-comments-on-form-222-extension-impact-on-psychedelics-20260723-24980The Psychedelic Journalen2026-07-23T15:06:55.934795+00:00DEA Seeks Comments on Form 222 Extension: Impact on PsychedelicsDEA Form 222, controlled substances, psychedelic research, regulatory compliance, Schedules I and II, drug enforcement, supply chain, legal framework, public comments, Paperwork Reduction Acthttps://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-impact-on-psychedelic-chemical-substances-20260723-24977The Psychedelic Journalen2026-07-23T15:06:41.987724+00:00EPA's Proposed SNURs: Impact on Psychedelic Chemical SubstancesEPA SNURs, Toxic Substances Control Act, chemical substances regulation, psychedelic research, regulatory compliance, manufacturing and processing, chemical evaluation, industry impact, regulatory delays, TSCA ruleshttps://mindmedicinelaw.com/briefing/fda-s-cmc-strategy-for-accelerated-psychedelic-therapies-20260723-24951The Psychedelic Journalen2026-07-23T15:06:29.824905+00:00FDA's CMC Strategy for Accelerated Psychedelic TherapiesFDA strategy, CMC readiness, psychedelic therapies, accelerated clinical development, PDUFA VII, drug manufacturing, regulatory approval, mental health treatments, product quality, clinical trialshttps://mindmedicinelaw.com/briefing/psycholytic-therapy-historical-insights-for-modern-psychedelic-research-20260722-25195The Psychedelic Journalen2026-07-23T22:06:34.839150+00:00Psycholytic Therapy: Historical Insights for Modern Psychedelic Researchpsycholytic therapy, psychedelic-assisted psychotherapy, LSD, therapeutic alliance, set and setting, clinical trials, historical review, psychedelic research, psychotherapy, therapeutic frameworkshttps://mindmedicinelaw.com/briefing/virtual-reality-s-role-in-transformative-experiences-20260722-25193The Psychedelic Journalen2026-07-23T22:06:24.152587+00:00Virtual Reality's Role in Transformative Experiencesvirtual reality, transformative experiences, epistemic expansion, positive emotions, mental health, therapeutic interventions, psychological well-being, VR technology, personal growth, clinical applicationshttps://mindmedicinelaw.com/briefing/advancing-treatment-resistant-depression-research-20260722-25204The Psychedelic Journalen2026-07-23T22:06:16.217752+00:00Advancing Treatment-Resistant Depression Researchtreatment-resistant depression, TRD research, staging in depression, measurement-based care, pharmacological interventions, demographic-specific burden, neuromodulation, depression subtypes, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/magnesium-ibogaine-in-tbi-treatment-emerging-insights-20260722-25194The Psychedelic Journalen2026-07-23T22:06:00.143240+00:00Magnesium-Ibogaine in TBI Treatment: Emerging Insightsmagnesium-ibogaine, traumatic brain injury, post-traumatic stress disorder, default mode network, mystical experiences, psychedelic-assisted treatment, veterans, clinical trials, neuroscience, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-therapy-for-grief-related-depression-a-new-frontier-20260722-24935The Psychedelic Journalen2026-07-23T15:07:25.127233+00:00Ketamine Therapy for Grief-Related Depression: A New Frontierketamine therapy, grief-related depression, psychedelic-assisted therapy, mental health treatment, clinical trials, Pacific Mind Health, FDA approval, psychedelic research, treatment-resistant depression, psychedelic markethttps://mindmedicinelaw.com/briefing/fda-s-regulatory-framework-for-psychedelics-in-the-us-20260722-24934The Psychedelic Journalen2026-07-23T15:07:11.733016+00:00FDA's Regulatory Framework for Psychedelics in the USFDA psychedelic regulation, psychedelic medicine, clinical trials, psilocybin, MDMA, mental health treatment, drug approval process, therapeutic benefits, market dynamics, patient carehttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-epilepsy-therapeutic-potential-and-challenges-20260721-24931The Psychedelic Journalen2026-07-23T22:06:46.174569+00:00Psilocybin's Role in Epilepsy: Therapeutic Potential and Challengespsilocybin therapy, epilepsy treatment, serotonergic therapy, clinical trials, neuroplasticity, psychedelic research, FDA regulations, neurological disorders, psychoactive effects, drug interactionshttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-decision-making-in-uncertain-contexts-20260721-25156The Psychedelic Journalen2026-07-23T22:06:07.714146+00:00Psilocybin's Impact on Decision-Making in Uncertain Contextspsilocybin, decision-making, psychiatric disorders, neural mechanisms, reinforcement learning, clinical applications, positive outcomes, uncertainty, therapeutic use, risk assessmenthttps://mindmedicinelaw.com/briefing/new-framework-for-multi-scale-disease-progression-20260721-24858The Psychedelic Journalen2026-07-23T15:07:34.773571+00:00New Framework for Multi-Scale Disease Progressionmulti-scale disease progression, compound race pathology, friction-theoretic framework, chronic disease treatment, Metabolic Control Analysis, multi-system dysregulation, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/psychedelics-in-treating-substance-use-disorders-emerging-research-20260721-24811The Psychedelic Journalen2026-07-22T22:04:44.843498+00:00Psychedelics in Treating Substance Use Disorders: Emerging Researchpsychedelics, substance use disorders, psilocybin, ketamine, treatment protocols, clinical trials, neuroplasticity, serotonin receptors, policy implications, longitudinal studieshttps://mindmedicinelaw.com/briefing/distinct-neural-mechanisms-of-ketamine-s-analgesic-and-dissociative-effects-20260720-24814The Psychedelic Journalen2026-07-22T22:05:25.285349+00:00Distinct Neural Mechanisms of Ketamine's Analgesic and Dissociative Effectsketamine, analgesia, dissociation, neural mechanisms, pain management, psychiatric disorders, fMRI study, placebo-controlled, default mode network, anterior insulahttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-dendritic-signaling-and-serotonin-receptors-20260720-24849The Psychedelic Journalen2026-07-22T22:05:16.631304+00:00Psilocybin's Impact on Dendritic Signaling and Serotonin Receptorspsilocybin, dendritic signaling, serotonin receptors, 5-HT2A receptor, psychedelic research, structural plasticity, mental health therapy, neuroscience, clinical trials, behavioral statehttps://mindmedicinelaw.com/briefing/ibogaine-s-potential-in-ketamine-use-disorder-treatment-20260720-24850The Psychedelic Journalen2026-07-22T22:04:53.388867+00:00Ibogaine's Potential in Ketamine Use Disorder Treatmentibogaine treatment, ketamine use disorder, substance use disorder, neuroplasticity, clinical trials, psychedelic therapy, polysubstance dependence, public health, NMDA antagonism, controlled trialshttps://mindmedicinelaw.com/briefing/eli-lilly-s-3-8b-investment-in-psychedelic-medicine-20260720-24936The Psychedelic Journalen2026-07-22T22:04:36.145903+00:00Eli Lilly's $3.8B Investment in Psychedelic Medicineeli lilly, psychedelic medicine, big pharma, clinical trials, mental health, research and development, regulatory approval, psilocybin, MDMA, pharmaceutical investmenthttps://mindmedicinelaw.com/briefing/tripartite-model-for-depression-in-oud-clinical-implications-20260713-22503The Psychedelic Journalen2026-07-22T15:05:57.398648+00:00Tripartite Model for Depression in OUD: Clinical Implicationstripartite model, opioid use disorder, depression, substance-induced depression, independent mood disorder, addiction-related depression, clinical practice, dual disorders, therapeutic strategies, diagnostic clarityhttps://mindmedicinelaw.com/briefing/idfa-model-a-new-approach-to-opioid-relapse-prevention-20260713-22494The Psychedelic Journalen2026-07-22T15:05:46.363246+00:00IDFA Model: A New Approach to Opioid Relapse Preventioninformational dysregulation framework, opioid use disorder, relapse prevention, neuroscience, clinical research, computational psychiatry, addiction treatment, information processing, public health policy, mechanism-informed interventionhttps://mindmedicinelaw.com/briefing/leonotis-leonurus-and-mentha-longifolia-antidepressant-potential-explored-20260713-22502The Psychedelic Journalen2026-07-22T15:05:33.486941+00:00Leonotis leonurus and Mentha longifolia: Antidepressant Potential ExploredLeonotis leonurus, Mentha longifolia, antidepressant potential, computational study, molecular docking, network pharmacology, depression treatment, traditional medicine, experimental validation, neurotransmitter systemshttps://mindmedicinelaw.com/briefing/psilocybin-s-behavioral-and-cellular-effects-implications-for-research-20260712-22388The Psychedelic Journalen2026-07-22T15:06:09.295391+00:00Psilocybin's Behavioral and Cellular Effects: Implications for Researchpsilocybin research, behavioral effects, cellular effects, clinical trials, psychedelic mechanisms, regulatory implications, therapeutic applications, neuroplasticity, serotonin receptors, psychiatric conditionshttps://mindmedicinelaw.com/briefing/alzheimer-s-dementia-new-pharmacological-targets-in-trials-20260710-22498The Psychedelic Journalen2026-07-22T15:06:18.001533+00:00Alzheimer's Dementia: New Pharmacological Targets in TrialsAlzheimer's dementia, pharmacological targets, Phase III trials, amyloid plaques, neurodegenerative diseases, clinical trials, therapeutic strategies, patient safety, cognitive declinehttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-anxiety-and-life-satisfaction-implications-20260708-24933The Psychedelic Journalen2026-07-22T22:05:04.816592+00:00DMT's Impact on Anxiety and Life Satisfaction: ImplicationsDMT, psychedelic therapy, anxiety improvement, life satisfaction, clinical guidelines, mental health treatment, neuroscience, quality of life, depression treatment